Abstract:Objective: During Toll-like receptor 4 signaling, the Toll/interleukin-1 receptor domain is essential for interactions with downstream Toll/interleukin-1 receptor domain-containing adaptor proteins. The aim of this study is to investigate the role of the Toll/interleukin-1 receptor domain in the Toll-like receptor 4 signaling pathway during hepatic ischemia and reperfusion injury.Design: We genetically blocked the function of Toll/interleukin-1 receptor domain in mice and examined the effect on Toll-like receptor 4 signaling and the response to hepatic ischemia and reperfusion.Setting: University research laboratory.Subjects: Male BALB/c mice.Interventions: Male BALB/c mice were hydrodynamically administrated the target gene plasmid pTIR-IRES2-EGFP, empty vector containing enhanced green fluorescent protein, or normal saline. Animals underwent 90 minutes of partial hepatic ischemia, followed by 6 or 24 hours of reperfusion. Hepatic injury was assessed by measuring serum alanine transaminase, hepatic histology, and malondialdehyde. The expression of inflammatory cytokines and nuclear factor-B phosphorylation was examined in liver tissues. Hepatic apoptosis was evaluated by caspase-3 assays, terminal deoxynucleotidyl transferase-mediated deoxyuridinetriphosphate nick-end labeling staining, and the activation of Jun N-terminal kinase and p38 mitogen-activated protein kinase.Measurements and Main Results: Blocking the Toll/interleukin-1 receptor domain resulted in markedly lower serum alanine transaminase levels, reduced histologic injury, and lower malondialdehyde levels following 6 or 24 hours of hepatic reperfusion than mice receiving the vector alone or normal saline. Anti-Toll/interleukin-1 receptor treatment also reduced Toll-like receptor 4 expression and disrupted Toll/interleukin-1 receptor-Toll/interleukin-1 receptor interactions in Toll-like receptor 4 signaling pathways. Blocking the Toll/interleukin-1 receptor domain also prevented Toll-like receptor 4-mediated mitogen-activated protein kinase activation (via Jun N-terminal kinase and p38 mitogen-activated protein kinase), an activation that mediated liver ischemia and reperfusion injury via caspase-3 activation, resulting in increased hepatocellular apoptosis. Lastly, blocking the Toll/interleukin-1 receptor domain decreased inflammatory cytokine production by inhibiting nuclear factor-B activation.Conclusions: Toll/interleukin-1 receptor domain inhibition disrupts the interaction of Toll-like receptor 4 with its adaptor proteins, which abrogates downstream signaling pathways and prevents the activation of nuclear factor-B and Jun N-terminal kinase/p38. This reduction in signaling consequently reduces hepatic inflammation, cell apoptosis, and hepatic damage. Toll/interleukin-1 receptor domain-targeted therapy thus represents a new approach to inhibit the intracellular Toll-like receptor 4 signaling pathway and reveals novel therapeutic target sites, which will facilitate the development of specific therapeutic agents.

Protection Against Hepatic Ischemia/reperfusion Injury Via Downregulation of Toll-Like Receptor 2 Expression by Inhibition of Kupffer Cell Function

Activation of Kupffer cell TLR2 signaling pathway during hepatic ischemia/reperfusion injury process in mice and it's significance]

Activation of Cyclic Adenosine Monophosphate-Dependent Protein Kinase a Signaling Prevents Liver Ischemia/reperfusion Injury in Mice

Inhibiting the Toll-Like Receptor 4 Toll/interleukin-1 Receptor Domain Protects Against Hepatic Warm Ischemia and Reperfusion Injury in Mice.

KEAP1-NRF2 Complex in Ischemia-Induced Hepatocellular Damage of Mouse Liver Transplants

Effect of GdCI3 on TLR2 Expression in Ischemic Lobes in Mouse Partial Liver Ischemia/reperfusion Injury

Ex Vivo Induced Regulatory T Cells Regulate Inflammatory Response of Kupffer Cells by Tgf-Beta and Attenuate Liver Ischemia Reperfusion Injury

Tauroursodeoxycholic Acid Alleviates Hepatic Ischemia Reperfusion Injury by Suppressing the Function of Kupffer Cells in Mice.

Endogenous Danger Signals Trigger Hepatic Ischemia/Reperfusion Injury Through Toll-Like Receptor 4/nuclear Factor-Kappa B Pathway

Influence of Kupffer Cells on Hepatic Signal Transduction As Demonstrated by Second Messengers and Nuclear Transcription Factors.

Inhibition of CKLF1 ameliorates hepatic ischemia-reperfusion injury via MAPK pathway

N-Acetylcysteine Inhibits Activation Of Toll-Like Receptor 2 And 4 Gene Expression In The Liver And Lung After Partial Hepatic Ischemia-Reperfusion Injury In Mice

Expression of Toll-Like Receptor 2 in Liver Kupffer Cells in Hepatic Ischemia/reperfusion Injury in the Mice

TAK242 suppresses the TLR4 signaling pathway and ameliorates DCD liver IRI in rats

Cellular-specific role of toll-like receptor 4 in hepatic ischemia-reperfusion injury in mice.

Targeting TRAF3 Signaling Protects Against Hepatic Ischemia/reperfusions Injury

Regulator of G‐protein signaling 14 protects the liver from ischemia–reperfusion injury by suppressing TGF‐β‐activated kinase 1 activation

Augmenter of Liver Regeneration Ameliorates Ischemia-Reperfusion Injury in Steatotic Liver Via Inhibition of the TLR4/NF-κB Pathway.

Role of programmed death ligand 1 and Kupffer cell in immune regulation after orthotopic liver transplantation in rats.

Regulator of G-protein signaling 14 protects the liver from ischemia reperfusion injury by suppressing TAK1 activation

TLR2 Mrna Upregulation in Ischemic Lobes in Mouse Partial Hepatic Ischemia/reperfusion Injury Model